Open access
96
Views
8
CrossRef citations to date
0
Altmetric
Original Research
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
Amanda L McDonell1 IMS Health, London, UKCorrespondence[email protected]
, Urpo Kiiskinen2 Eli Lilly and Company, Helsinki, Finland
, Danielle C Zammit3 IMS Health, Basel, Switzerland
, Robert W Kotchie1 IMS Health, London, UK
, Per-Olof Thuresson3 IMS Health, Basel, Switzerland
, Claudia Nicolay4 Eli Lilly and Company, Bad Homburg, Germany
, Thomas Haslam1 IMS Health, London, UK
, Michiel Bruinsma5 IMS Health, Rotterdam, the Netherlands
, Anne-Jeanine Janszen-Van Oosterhout6 Eli Lilly Nederland, Houten, the Netherlands
& Thorsten Otto4 Eli Lilly and Company, Bad Homburg, Germany
show all
Pages 95-103
|
Published online: 30 Jan 2015
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.